Quick Answer: NAC (N-acetyl-L-cysteine) is still on sale, but its legal status as a dietary supplement has been unsettled. Because NAC was approved as a drug (Mucomyst) in 1963, before anyone sold it as a supplement, federal law excludes it from the supplement definition, and since August 2022 NAC supplements have been sold under FDA enforcement discretion. On November 16, 2026 the FDA announced, and on November 17 published, a proposed rule (Docket FDA-2025-N-2699) that would make NAC a lawful supplement ingredient, the first time the agency has used this power. FDA says its systematic review of 41 high-confidence studies (doses up to 9,000 mg/day, up to 3 years) found a “minimal” level of concern, mainly mild stomach upset. Comments close January 19, 2027. Nothing changes for shoppers today: the rule is not final, and FDA says enforcement discretion continues in the meantime.
The Proposed Rule at a Glance
| Item | Detail |
|---|---|
| What it does | Creates 21 CFR 190.1, “Dietary ingredients not excluded from the dietary supplement definition,” and lists N-acetyl-L-cysteine as its first (and only) entry |
| Announced | FDA constituent update, November 16, 2026 |
| Published | Federal Register, November 17, 2026 (91 FR 73717, FR Doc. 2026-23351) |
| Docket | FDA-2025-N-2699 (RIN 0910-AI91) |
| Comment deadline | January 19, 2027, 11:59 p.m. Eastern, at regulations.gov |
| Proposed effective date | Immediately on publication of a final rule |
| Until then | FDA’s August 2022 enforcement discretion policy stays in place |
| Safety finding | “Minimal” level of concern from a peer-reviewed systematic review of oral NAC |
What the FDA Actually Proposed
The proposal is short. It would add one regulation saying that certain ingredients, which would otherwise be excluded from the definition of “dietary supplement,” are not excluded, and that adding them to a supplement is not a prohibited act under section 301(ll) of the Federal Food, Drug, and Cosmetic Act. Paragraph (a) names N-acetyl-L-cysteine. Paragraph (b) is reserved, which leaves room for FDA to list other ingredients later.
If finalized, NAC products labeled as supplements would be regulated like any other supplement, “provided that such products are not otherwise in violation of the FD&C Act,” in FDA’s words. That includes current good manufacturing practice rules (21 CFR part 111), labeling rules, and enforcement against adulterated or misbranded products. FDA says it would then withdraw its 2022 enforcement discretion guidance. The agency also calls this its first use of the rulemaking authority in the exclusion clause of the supplement definition.
Why NAC Has Been in Legal Limbo
Federal law says a product cannot be a dietary supplement if it contains an article that was approved as a new drug before it was marketed as a supplement or food, unless FDA issues a regulation, after notice and comment, finding the use lawful. FDA approved acetylcysteine as Mucomyst (NDA 013601), an inhaled drug for thinning mucus, on September 14, 1963. The earliest NAC supplement marketing FDA has found is an advertisement from August/September 1991. On that timeline, NAC is a dietary ingredient but has been excluded from the supplement definition since Congress wrote it in 1994. FDA’s own proposal says firms “illegally continued” to sell NAC products labeled as supplements for more than 30 years.
| Date | Event (as described in the Federal Register notice) |
|---|---|
| Sept 14, 1963 | FDA approves acetylcysteine (Mucomyst, NDA 013601) as a new drug |
| Aug/Sept 1991 | Earliest known advertisement for an NAC-containing supplement |
| July 2001 | FDA cites the exclusion when a health claim petition for an NAC product is denied (letter now being placed in the docket) |
| 2004 | Injectable acetylcysteine (Acetadote, NDA 021539) approved as an acetaminophen overdose antidote |
| 2009 | Mucomyst NDA withdrawn at the sponsor’s request, for reasons other than safety or effectiveness |
| 2010 | FDA repeats the exclusion in response to an NDI notification for NAC ethyl ester |
| July 2020 | FDA warning letters to hangover-product sellers state NAC products are excluded from the supplement definition |
| 2021 | Two citizen petitions ask FDA to reverse its position or open rulemaking |
| March 31, 2022 | FDA denies one petition and partly denies the other, but leaves the rulemaking request open |
| August 2022 | Final guidance: temporary enforcement discretion for NAC products labeled as supplements |
| Nov 16–17, 2026 | Proposed rule announced and published; comments due January 19, 2027 |
The 2020 warning letters were aimed at products that claimed to cure, treat, mitigate or prevent hangovers. That detail matters: even after the rule, a supplement cannot make disease claims, as the law firm Venable notes in its analysis of the proposal. The rule settles NAC’s ingredient status; it does not license therapeutic marketing.
What FDA’s Safety Review Found
Because drug approvals weigh benefit against risk while supplement safety looks only at risk, FDA did a separate systematic review of studies of orally taken NAC, mostly outside its approved drug uses. The protocol, analysis and conclusions went through external peer review, according to the notice. Key findings as FDA reports them:
- 41 high-confidence studies were used for conclusions on adverse events and exposure.
- Doses ranged from 200 mg to 9,000 mg per day, for 5 days to 3 years, in groups from healthy volunteers to patients with end-stage kidney disease. High doses and long durations did not show more adverse-event reporting.
- The most commonly reported effects were stomach pain or discomfort, nausea, vomiting and rash. Only one study found a statistically significant increase, in non-serious nausea.
- Supplement labels most often suggest 600, 1,000 or 1,200 mg per day, which overlaps with the doses studied (several trials used 1,200 mg/day).
- FDA rated the result a “minimal” level of concern on the National Toxicology Program’s five-point scale and concluded there is “a reasonable expectation of safety” for NAC in or as a supplement.
Two limits are worth keeping in mind. A safety review is not evidence that NAC works for any particular purpose; for that, see our NAC vs glutathione comparison. And the review concerns NAC itself, not every product on the shelf, so quality still depends on the manufacturer.
NAC the Drug vs NAC the Supplement
| Prescription acetylcysteine | NAC supplement | |
|---|---|---|
| Status | FDA-approved drug since 1963; at least 19 generic applications (ANDAs) in the Orange Book | Sold under enforcement discretion since 2022; proposed rule would make it lawful |
| Approved uses | Preventing or lessening liver injury after acetaminophen overdose; adjunct for thick mucus in conditions such as chronic bronchopulmonary disease | No approved uses; may carry structure/function claims only, not disease claims |
| Forms | Injectable Acetadote (approved 2004) and generic acetylcysteine products; the original Mucomyst NDA was withdrawn in 2009 | Oral capsules, tablets and powders, commonly 600–1,200 mg per serving |
| Standard of review | Benefit versus risk for a disease | Risk only, at dietary doses |
| Who uses it | Patients treated by clinicians, e.g. in an emergency department | Consumers choosing it for general wellness |
FDA also looked at whether supplement sales could hurt drug research, the second test it applies. It counted 832 clinical trials of NAC as a drug and noted that most of the 19 generic approvals came after 1991, when supplement sales began. It concluded that more than 30 years of supplement sales “does not appear to have negatively impacted NAC drug development,” and that no one who commented on the 2022 guidance showed otherwise.
Not a do-it-yourself overdose treatment: acetylcysteine is a hospital antidote for acetaminophen (Tylenol) overdose, given under medical supervision. A store-bought NAC capsule is not a substitute. If someone may have taken too much acetaminophen, call Poison Control at 1-800-222-1222 or 911 right away.
What Changes for People Who Take NAC
Right now, nothing. The rule is only proposed. FDA says it “intends to continue this enforcement discretion while we work through the rulemaking process,” so the NAC products currently sold can stay on the market. If the rule becomes final as written, it would take effect immediately on publication, and the change would mostly be legal certainty:
- Firmer footing for retailers. FDA’s economic analysis says firms may respond to the legal clarity by introducing new products, though it does not estimate how likely that is.
- Full supplement rules apply. NAC products would clearly fall under supplement manufacturing (CGMP) and labeling requirements, and FDA could act against adulterated or misbranded ones.
- Claims stay limited. Labels can describe effects on normal structure or function but cannot claim to treat or prevent disease, such as hangovers.
- Precedent for other ingredients. The reserved paragraph (b) means other drug-first ingredients could, in principle, be added later through the same process.
Who Should Do What
- If you take NAC now: you do not need to stop or stock up because of this rule. Keep buying from brands that use third-party testing, and tell your clinician you take it, since our NAC guide notes possible interactions with nitroglycerin, blood thinners and some chemotherapy drugs.
- If you are considering NAC: the FDA review speaks to safety at common doses, not benefit. Weigh the evidence for your specific goal and talk to your doctor, especially if you are pregnant, breastfeeding or take prescription medicines.
- If you want a say: anyone can comment at regulations.gov under Docket FDA-2025-N-2699 until January 19, 2027. FDA specifically asks for evidence of NAC being sold as a food or supplement before September 14, 1963, and for data on any effect on drug development. Comments are posted publicly, so leave out personal medical details.
Frequently Asked Questions
Is NAC banned in the US?
No. NAC supplements are still sold. Legally, NAC has been excluded from the dietary supplement definition because it was approved as a drug in 1963, but since August 2022 FDA has used enforcement discretion to let NAC supplements stay on the market. A November 2026 proposed rule would make that status permanent and lawful.
What did the FDA propose about NAC in November 2026?
FDA proposed a new regulation, 21 CFR 190.1, saying N-acetyl-L-cysteine is not excluded from the dietary supplement definition. It was announced November 16 and published in the Federal Register on November 17, 2026 (Docket FDA-2025-N-2699). It is the first time FDA has used this authority.
When does the NAC rule take effect?
Not yet. It is a proposed rule, and comments are open until January 19, 2027. FDA proposes that a final rule take effect immediately when published. Until then, FDA says its 2022 enforcement discretion policy continues.
Did the FDA find NAC safe?
FDA's systematic review of 41 high-confidence studies of oral NAC, with doses up to 9,000 mg a day for up to 3 years, found a minimal level of concern. The most common side effects were mild stomach upset, nausea, vomiting and rash. That is a safety finding, not proof that NAC works for any purpose.
Why was NAC excluded from supplements in the first place?
Federal law excludes an ingredient from supplements if it was approved as a drug before it was sold as a supplement or food. Acetylcysteine was approved as Mucomyst on September 14, 1963, and the earliest NAC supplement ad FDA has found is from 1991.
Will NAC supplements be able to claim they treat hangovers?
No. Supplements cannot claim to treat, cure or prevent disease. FDA's 2020 warning letters were sent to hangover products containing NAC, and the proposed rule only settles NAC's ingredient status, not marketing claims.
How can I comment on the NAC proposed rule?
Go to regulations.gov, search Docket FDA-2025-N-2699, and submit by 11:59 p.m. Eastern on January 19, 2027. Comments are posted publicly, so do not include private medical information.
Sources
- FDA proposed rule: Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition. Federal Register 91 FR 73717, Docket FDA-2025-N-2699. November 17, 2026
- FDA Constituent Update: FDA Issues Proposed Rule on NAC Products as Dietary Supplements. November 16, 2026
- FDA Guidance for Industry: Policy Regarding N-acetyl-L-cysteine (enforcement discretion). August 2022
- FDA Warning Letter to Vita Heaven LLC (Hangover Heaven), one of the July 23, 2020 NAC hangover-product letters cited in the proposed rule
- Venable LLP. FDA Proposes First-Ever Rule Under the Drug Exclusion Exception: NAC Would Be a Lawful Dietary Supplement Ingredient. November 18, 2026
- Regulations.gov: Docket FDA-2025-N-2699 (comments and supporting documents)
Medical disclaimer: This article explains a proposed federal rule and is for educational purposes only. It is not legal or medical advice. Consult a licensed healthcare provider before starting any supplement, medication, or treatment — particularly if you are pregnant, breastfeeding, taking other medications, or have a diagnosed medical condition.